Rev 1: September 2018 FSN Ref: FSN_CAPA-2022-031_en_final FUJIFILM medwlQlrk

FSCA Ref: FSCA_CAPA-2022-031

Date: 24.08.2022

Field Safety Notice CrossSnare


Dear customer

FUJIFILM medwork GmbH as manufacturer of the CrossSnare product, hereby notities about the issue of a Field Safety Corrective Action relating to the aforementioned product.

FUJIf=ILM medwlQlrk

FSCA Ref: FSCA_CAPA-2022-031

Field Safety Notice (FSN) CrossSnare Elevated EO residuals



2 Reason for Field Safety Corrective Action FSCA *
1. Description of the product problem*

FUJ FILM medwlQlrk

Rev 1: September 2018 FSN Ref: FSN_CAPA-2022-031_en_final

FSCA Ref: FSCA_CAPA-2022-031

2	DIN EN ISO 10993-7 defines values for EO and ECH residuals in EO sterilized products. Lab test results of POL1-X products showed elevated values for EO after the degassing
	period.
2	2. Hazard givina rise to the FSCA*
	As long as the limit values are exceeded the products might pose a small potential threat to the health of users or oatients (headache nausea or vertiao).
2	3. Probability of problem arising
	There is a very small chance that above-mentioned symptoms might occur if the products
	are acolied in a clinical procedure. During storage no harm is present.
2	 Predicted risk to oatient/users
	Headache nausea or vertigo miaht occur.

		Type of Action to mitigate the risk*			
3.	1.	Action To Be T	aken by the Use		
		D Identify Device	D Quarantine Device	□ Return Device	D Destroy Device
		□ On-site device modification/inspection			
		□ Follow patient management recommendations			
		□ Take note of amendment/reinforcement of Instructions For Use (IFU)			
		□ Other	181 None		

FUJ FILM medwlQlrk

Rev 1: September 2018
FSN Ref: FSN_CAPA-2022-031_en_final

FSCA Ref: FSCA_CAPA-2022-031

	4. General Information*				
4.	1. FSN Type*	Update			
4.	 For updated FSN, reference number and date of previous FSN 	FSN_CAPA-2022-031 dated 04.08.2022			
	3. For Updated FSN, key new information as fellows:				
4	The repetition of the residual gas determination on the product POL1-X1-15-23-220- OL, LOT 22252794 after 21 days of storage after completion of the post-conditioning phase of sterilisation (TQL 21) resulted in a significantly reduced value of 0.88 mg EO per product. The permitted limit of 4 mg per product according to DIN EN ISO 10993-7 is thus complied with. Goeds of the affected products POL1-X1-15-23-220- OL and POL1-X1-10-23-220-OL that have been stored for 21 days can be released for sale and use.				
4.	 Manufacturer information (For contact details of local representative refer to pacie 1 of this FSNJ 				
	a. Company Name	FUJIFILM medwork GmbH			
	b. Address	Medworkring 1, 91315 Höchstadt			
	c. Website address	www.medwork.com			
4.	5. The Competent (Regulatory) Authority of your country has been informed about this communication to customers. *				
4.	6. Name/Signature				

Transmission of this Field Safety Notice
This notice needs to be passed on all those who need to be aware within your organisation or to any organisation where the potentially affected devices have been transferred. (As appropriate)
Please transfer this notice to other organisations on which this action has an impact. (As appropriate)
Please maintainawareness on this noticeand resulting action for an appropriate period to ensure effectiveness of the corrective action.
Please report all device-related incidents to the manufacturer, distributor or local representative, and the national Comoetent Authoritv if aoorooriate as this orovides important feedback.*

Note: Fields indicated by * are considered necessary for all FSNs. Others are optional.